# Vyriad

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vyriad

- Industry: Biotechnology
- Headquarters: US
- Website: www.vyriad.com
- Total disclosed funding: $30M
- Latest round: Series B (May 17, 2022)
- Investors on record: 4

## About

Based in Minnesota, US, and founded in 2015 by Stephen J. Russell (CEO), and Kah-Whye Peng (CTO), Vyriad, Inc. operates as a biotechnology company that provides clinical-stage developing oncolytic virus therapies to treat a wide range of cancers. In May 2022, Vyriad, Inc. raised USD 29.5 Million in Series B funding led by Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals, and Southeast Minnesota Capital Fund. In December 2025, Vyriad, Inc. raised USD 25 million in series B funding led by an individual investor.

Vyriad, Inc. is a diagnostic company that fights cancer cells, activates immune responses, and stops cancer recurrence. Furthermore, the company provides oncolytic virus therapies that use engineered viruses to target ovarian cancer, glioblastoma, mesothelioma, head and neck cancer, blood cancers, endometrial cancer, hematologic malignancies, and multiple myeloma, where, healthcare organizations provide patients with oncolytic virotherapy and develop potent, safe, and cost-effective cancer therapies in areas of unmet need.

The company plans to use the December 2025 funding to begin human testing of its genetic therapy candidate, support development of its targeted viral treatments, and advance clinical programs for cancers and other serious diseases.

## Funding rounds

- Series B, May 17, 2022, $30M — Mayo Clinic, Mirae Asset Global Investments, Regeneron Pharmaceuticals, Inc., Southeast Minnesota Capital Fund
- Seed, Aug 21, 2018, $0.5M — Southeast Minnesota Capital Fund

## Investors

- Southeast Minnesota Capital Fund (https://capitalatlas.ai/funds/southeast-minnesota-capital-fund) — Seed, Series B
- Mayo Clinic — Series B
- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series B
- Regeneron Pharmaceuticals, Inc. — Series B